NASDAQ:STMLStemline Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stemline Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.83 0.00 (0.00 %) (As of 06/10/2020) Add Compare Share Today's Range$11.83Now: $11.83▼$11.8350-Day Range$11.83MA: $11.83▼$11.8352-Week Range$3.21Now: $11.83▼$18.22Volume1,084 shsAverage Volume1.52 million shsMarket Capitalization$621.21 millionP/E RatioN/ADividend YieldN/ABeta1.78 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingStemline Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.31, Stemline Therapeutics has a potential downside of 4.4% from its current price of $11.83.Amount of Analyst CoverageStemline Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesStemline Therapeutics has received 446 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStemline Therapeutics has received 256 “underperform” votes. (Add your “underperform” vote.)Community SentimentStemline Therapeutics has received 63.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote “Outperform” if you believe STML will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStemline Therapeutics does not currently pay a dividend.Dividend GrowthStemline Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stemline Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.20% of the stock of Stemline Therapeutics is held by insiders.Percentage Held by Institutions75.80% of the stock of Stemline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stemline Therapeutics are expected to grow in the coming year, from ($1.31) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stemline Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stemline Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStemline Therapeutics has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.2Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STML Previous Symbol CUSIPN/A CIK1264587 Webwww.stemline.com Phone646-502-2311Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$43.22 million Price / Sales14.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book3.63Profitability EPS (Most Recent Fiscal Year)($1.83) Net Income$-76,820,000.00 Net Margins-150.30% Return on Equity-48.14% Return on Assets-41.35%Miscellaneous Employees92 Outstanding Shares52,511,000Market Cap$621.21 million Next Earnings DateN/A OptionableOptionable Receive STML News and Ratings via Email Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter. Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Stemline Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Stemline Therapeutics. How were Stemline Therapeutics' earnings last quarter? Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative return on equity of 48.14%. View Stemline Therapeutics' earnings history. What price target have analysts set for STML? 8 analysts have issued 12-month price targets for Stemline Therapeutics' shares. Their forecasts range from $8.00 to $12.50. On average, they anticipate Stemline Therapeutics' share price to reach $11.31 in the next year. This suggests that the stock has a possible downside of 4.4%. View analysts' price targets for Stemline Therapeutics. Has Stemline Therapeutics been receiving favorable news coverage? Media coverage about STML stock has been trending extremely negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Stemline Therapeutics. Are investors shorting Stemline Therapeutics? Stemline Therapeutics saw a drop in short interest in the month of May. As of May 29th, there was short interest totaling 2,810,000 shares, a drop of 14.3% from the May 14th total of 3,280,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is presently 1.5 days. View Stemline Therapeutics' Short Interest. Who are some of Stemline Therapeutics' key competitors? Some companies that are related to Stemline Therapeutics include Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB), Eidos Therapeutics (EIDX) and Madrigal Pharmaceuticals (MDGL). View all competitors. What other stocks do shareholders of Stemline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Gilead Sciences (GILD), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Teva Pharmaceutical Industries (TEVA). Who are Stemline Therapeutics' key executives? Stemline Therapeutics' management team includes the following people: Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)Mr. Robert Francomano, Sr. VP & Global Head of CommercialMr. John A. Salvagno, Sr. VP of Quality & Operations What is Stemline Therapeutics' stock symbol? Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML." What is Stemline Therapeutics' stock price today? One share of STML stock can currently be purchased for approximately $11.83. How big of a company is Stemline Therapeutics? Stemline Therapeutics has a market capitalization of $621.21 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76,820,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe. What is Stemline Therapeutics' official website? The official website for Stemline Therapeutics is www.stemline.com. How can I contact Stemline Therapeutics? Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
